bioAffinity Technologies Announces Live Virtual Physician Roundtable on CyPath® Lung Integration
Key Highlights from the Report
- Event Announcement: bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) will host the inaugural session of its “CyPath® Lung in Practice” webinar series on April 8, 2026. This live virtual roundtable will focus on integrating CyPath® Lung, the company’s noninvasive lung cancer diagnostic test, into clinical practice.
- Clinical Focus: The webinar will feature leading pulmonologists sharing real-world patient cases, emphasizing CyPath® Lung’s role in lung cancer risk assessment, managing indeterminate pulmonary nodules, and monitoring lung cancer survivors post-treatment.
- Product Performance: CyPath® Lung demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer among high-risk patients with small indeterminate nodules (less than 20mm), according to clinical studies.
- Panel Composition: The event will be moderated by Dr. Gordon H. Downie, Chief Medical Officer of bioAffinity Technologies, and will include notable pulmonologists practicing advanced diagnostic and therapeutic techniques.
- Commercialization and Market Adoption: CyPath® Lung is currently marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.
- Forward-Looking Statements: The company cautions potential risks related to the commercialization and adoption of CyPath® Lung, regulatory approvals, and other uncertainties that may affect future performance and share value.
Detailed Analysis for Investors
bioAffinity Technologies, Inc., a leader in noninvasive diagnostics and early cancer detection, has announced a significant upcoming event: a live virtual physician roundtable to discuss the integration and clinical utility of its flagship diagnostic test, CyPath® Lung.
Webinar Details and Strategic Importance
- Date/Time: April 8, 2026, at 7 p.m. ET/6 p.m. CT (registration link: here).
- Target Audience: Pulmonologists and other healthcare professionals interested in enhancing lung cancer detection through noninvasive means.
- Format: Live Zoom event, with a recording made available on the CyPath® Lung website for continued reference and education.
This initiative signals the company’s proactive strategy to drive education and awareness among key stakeholders, which is crucial for accelerating the adoption of CyPath® Lung in clinical settings. The inclusion of real-world case studies and interactive discussions aims to demonstrate the tangible benefits of the test, which may positively influence physician uptake and, consequently, revenue growth.
Panel of Experts
- Moderator: Dr. Gordon H. Downie, MD, PhD – Chief Medical Officer of bioAffinity Technologies, with 35+ years in pulmonary medicine and cancer diagnostics.
- Dr. Sai Karan Vamsi Guda, DO: Interventional pulmonologist (Texas Pulmonary & Critical Care Consultants), expert in robotic bronchoscopy and minimally invasive lung disease management.
- Dr. Michael Nicholson, DO: Pulmonologist and critical care specialist (RWJBarnabas Health Medical Group, NJ), focuses on noninvasive malignancy risk stratification.
- Dr. Gregory White, MD: Pulmonologist (CHRISTUS Trinity Clinic), specializes in advanced bronchoscopy and comprehensive pulmonary care, including lung cancer, asthma, and COPD.
CyPath® Lung: Clinical and Market Potential
- CyPath® Lung utilizes advanced flow cytometry and proprietary artificial intelligence to analyze patient sputum for cell populations indicative of malignancy.
- A fluorescent porphyrin, preferentially taken up by cancer and cancer-related cells, forms the core of its detection method.
- Clinical study results are compelling: 92% sensitivity, 87% specificity, and 88% accuracy in high-risk patients with small, indeterminate nodules (less than 20mm).
- This level of performance positions CyPath® Lung as a potential game-changer in early lung cancer detection, which could lead to better patient outcomes and reduce unnecessary invasive procedures.
Potential Impact on Shareholder Value
- Adoption and Commercialization: The company’s efforts to educate and engage physicians directly may accelerate adoption and positively impact sales growth, making this event price-sensitive.
- Regulatory Status: CyPath® Lung is currently offered as an LDT, regulated under CLIA by the Centers for Medicare & Medicaid Services. Further regulatory milestones or commercial partnerships may serve as future catalysts.
- Forward-Looking Risks: Shareholders should note the company’s caution regarding potential commercialization risks, market acceptance, and regulatory hurdles. Any developments in these areas could materially affect share value.
Contact Information
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the company’s official regulatory filings and consult with their financial advisors before making any investment decisions. Future outcomes may differ from current expectations due to various risks and uncertainties as outlined in the company’s filings with the SEC.
View bioAffinity Technologies, Inc. Historical chart here
